The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 12, 2024
Filed:
Sep. 18, 2020
Applicant:
Cava Healthcare Inc., Vancouver, CA;
Inventors:
Wilfred Jefferies, Surrey, CA;
Kaan E. Biron, North Vancouver, CA;
Dara L. Dickstein, New York, NY (US);
Assignee:
Cava Healthcare Inc., Vancouver, CA;
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); A61K 31/05 (2006.01); A61K 31/192 (2006.01); A61K 31/404 (2006.01); A61K 31/42 (2006.01); A61K 31/436 (2006.01); A61K 31/44 (2006.01); A61K 31/506 (2006.01); A61K 31/551 (2006.01); A61K 38/17 (2006.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); A61K 38/39 (2006.01); A61K 38/48 (2006.01); A61K 39/00 (2006.01); A61K 47/64 (2017.01); C07K 16/18 (2006.01); C07K 16/22 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0007 (2013.01); A61K 31/05 (2013.01); A61K 31/192 (2013.01); A61K 31/404 (2013.01); A61K 31/42 (2013.01); A61K 31/436 (2013.01); A61K 31/44 (2013.01); A61K 31/506 (2013.01); A61K 31/551 (2013.01); A61K 38/1709 (2013.01); A61K 38/195 (2013.01); A61K 38/208 (2013.01); A61K 38/21 (2013.01); A61K 38/212 (2013.01); A61K 38/39 (2013.01); A61K 38/484 (2013.01); C07K 16/18 (2013.01); C07K 16/22 (2013.01); G01N 33/5058 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/575 (2013.01);
Abstract
Methods for diagnosing and treating Alzheimer's disease are provided. In particular, methods of restoring blood-brain barrier integrity and/or promoting vascular reversion in a person suffering from Alzheimer's disease by administering an anti-angiogenic agent or an agent that is capable of restoring tight junction integrity. Methods of preventing or delaying the onset of Alzheimer's disease in a subject are also provided.